PT  - JOURNAL ARTICLE
AU  - Teklay Gebrecherkos
AU  - Zekarias Gessesse
AU  - Yazezew Kebede
AU  - Atsbeha Gebreegzabher
AU  - Geremew Tasew
AU  - Mahmud Abdulkader
AU  - Hiluf Ebuy
AU  - Abraham Desta
AU  - Atakilti Hailu
AU  - Vanessa Harris
AU  - Tobias Rinke de Wit
AU  - Dawit Wolday
TI  - Effect of co-infection with parasites on severity of COVID-19
AID  - 10.1101/2021.02.02.21250995
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.02.21250995
4099  - http://medrxiv.org/content/early/2021/02/03/2021.02.02.21250995.short
4100  - http://medrxiv.org/content/early/2021/02/03/2021.02.02.21250995.full
AB  - Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection results in a spectrum of clinical presentations. The effect of co-infection with parasites on the clinical features of COVID-19 is unknown.Methods We prospectively enrolled consecutive COVID-19 patients and screened them for intestinal parasitic infections. Patients were followed during hospitalization for clinical outcomes. Patients with parasitic co-infection were compared to those without parasitic co-infection. The primary outcome was the proportion of COVID-19 patients who developed severe disease. Factors associated with the development of severe disease were determined by logistic regression.Results A total of 515 patients with PCR-confirmed SARS-CoV-2 infection were screened for intestinal parasites, of whom 267 (51.8%) were co-infected with one or more parasites. Parasitic co-infection correlated inversely with COVID-19 severity. Severe COVID-19 was significantly higher in patients without parasites [47/248 (19.0%, CI: 14.52-24.35)] than in those with parasites [21/267 (7.9%, CI: 5.17-11.79)]; p<0.0001. There was a significantly higher proportion of patients who developed severe COVID-19 in the non-protozoa group [56/369 (15.2%, CI: 11.85-19.23)] as compared to the protozoa group [12/146 (8.2%, CI: 4.70-14.00)]; p=0.036. Significant higher proportion of the patients presented at baseline with severe COVID-19 in the helminth negative group [57/341 (16.7%, CI: 13.10 – 21.08)] than in the group with pre-existing helminth infection [11/174 (6.3%, CI: 3.51 – 11.11)]; p=0.001. In addition, after adjustment for age and presence of comorbidities, COVID-19 patients with any parasite co-infection [aOR 0.41 (95% CI: 0.22–0.77); p=0.006], or with protozoa co-infection [aOR 0.45 (95% CI: 0.21–0.98); p=0.044] as well as those with helminth co-infection [aOR 0.37 (95% CI: 0.17–0.80); p=0.011] had lower probability of developing severe COVID-19 compared with those without parasite, protozoa or helminth co-infection.Conclusion Our results suggest that co-infection with parasitic co-infection appears to be associated with reduced COVID-19 severity. The results suggest that parasite-driven immunomodulatory responses may mute hyperinflammation associated with severe COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04473365Funding StatementThis research was supported by grants from the European and Developing Countries Clinical Trials Partnership (EDCTP), supported by the European Union (RIA-2020EF-2095) and Joep Lange Institute for Global Health and Development, The Netherlands.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed and approved by the Health Research Ethics Review Committee (HRERC) of Mekelle University College of Health Sciences (#ERC 1769/2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request. All requests to access the data must be processed through the project Research Steering Committee. All data accessibility requests should be directed to the corresponding authors.